Skip to Content

Join the 'Peripheral T-cell Lymphoma' group to help and get support from people like you.

Peripheral T-cell Lymphoma News

Related terms: PTCL

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

Posted 3 Jul 2014 by Drugs.com

July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. PTCL comprises a diverse group of rare diseases in which lymph nodes become cancerous. In 2014, the N ...

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma

Posted 3 Jul 2014 by Drugs.com

THURSDAY, July 3, 2014 – Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes). Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute ...

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma

Related Drug Support Groups

Folotyn, Istodax, pralatrexate, romidepsin, belinostat, Beleodaq